详情页 - 河北大学附属医院知识库

当前位置：首页 > 详情页

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2e) breast cancer (BC): Results from TROPION-Breast01 China cohort

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Medical Oncology, Cancer Center of Sun Yat-sen University, Guangzhou, China [2]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China [3]Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China [4]Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, He Xi District, China [5]Department of Oncology, First Hospital of Jilin University, Changchun, China [6]Department the 2nd Ward of Breast Surgery, Linyi Cancer Hospital, Linyi, China [7]Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China [8]Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China [9]Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China [10]Department of Oncology, Jinan Central Hospital, Shandong First Medical University, Jinan, China [11]Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China [12]Department of Breast Surgery, Peking University People’s Hospital, Beijing, China [13]Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Hebei, China [14]Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China [15]Department of Medical Oncology, The Third Hospital of Nanchang, Nanchang, Jiangxi Province, China [16]Department of Medical Oncology, Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China [17]Breast Surgery, Hospital of Sichuan University, Chengdu, China [18]Thyroid and Breast Surgery Department, Changhai Hospital of Shanghai, Shanghai, China [19]Department of Medicine, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA [20]Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

出处：

DOI：

ISSN：

摘要：

Background: In the global, phase III TROPION-Breast01 study (NCT05104866), the TROP2-directed antibody-drug conjugate Dato-DXd showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) vs investigator’s choice of CT (ICC) (HR 0.63 [95% CI 0.52‒0.76]; p<0.0001) (Bardia et al, ESMO 2023) in pts with pre-treated inoperable/metastatic HR+/HER2eBC. Here we present efficacy and safety data from pts enrolled in mainland China.

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

影响因子： 65.4 最新[2024版] 46.8 最新五年平均 65.4 出版当年[2024版] 46.8 出版当年五年平均 56.7 出版前一年[2023版]

第一作者：

第一作者机构： [1]Medical Oncology, Cancer Center of Sun Yat-sen University, Guangzhou, China

推荐引用方式(GB/T 7714)：

APA：

MLA：